Prelude Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Prelude Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.4K	Sell	24,015 -24,000	-50%	-$41.9K	﹤0.01%	1145
2025 Q4	$116K	Buy	+48,015	New	+$104K	0.01%	1164
2025 Q2	–	Sell	-13,067	Closed	-$26.5K	–	984
2025 Q1	$26.5K	Buy	+13,067	New	+$70.3K	﹤0.01%	1121
2024 Q4	–	Sell	-37,727	Closed	-$264K	–	1185
2024 Q3	$264K	Buy	+37,727	New	+$297K	0.02%	932
2024 Q2	–	Sell	-13,000	Closed	-$93K	–	1187
2024 Q1	$93K	Buy	+13,000	New	+$60.3K	﹤0.01%	1209

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's ACRV Position: Q1 2026 in Review

Prelude Capital Management reduced its Acrivon Therapeutics (ACRV) stake by 50% in Q1 2026, selling an estimated $41.9K and leaving 24,015 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.

Prelude Capital Management first reported a position in ACRV in Q1 2024 and has held it in 5 quarters since. The position peaked at $264K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Prelude Capital Management held 24,015 shares of Acrivon Therapeutics worth $33.4K as of Q1 2026.
Prelude Capital Management sold 24,000 Acrivon Therapeutics shares in Q1 2026, an estimated $41.9K.
Acrivon Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1145 holding.
Prelude Capital Management first reported a position in Acrivon Therapeutics in Q1 2024 and has held it in 5 quarters since.
Prelude Capital Management's Acrivon Therapeutics position peaked at $264K in Q3 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.